Implementation of the Fatty Liver Index in Primary Care (FLI-AP)

C

Consorci Sanitari de l'Alt Penedès i Garraf

Status

Not yet enrolling

Conditions

Overweight and Obesity
Hepatic Steatosis

Treatments

Other: FLI

Study type

Interventional

Funder types

Other

Identifiers

NCT06363617
CSAPG-58

Details and patient eligibility

About

This trial aims to evaluate the impact on cardiovascular risk control in individuals in risk of being affected by hepatic steatosis through the implementation of a screening test (Fatty Liver Index) in Primary Care. Medical teams in a primary care center will be divided into 2 groups, with one group using the screening test in their clinical practice. The number of interventions on cardiovascular risk occurring in patients attended by each group of medical teams will be evaluated and compared.

Enrollment

434 estimated patients

Sex

All

Ages

14+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Men and women aged 14 years and older.
  • Attended at the Basic Care Units (BCU) participating in the Primary Care Center Baix a Mar study.
  • Intention to undergo medical follow-up at the study center.
  • Body mass index ≥ 25.

Exclusion criteria

  • Pregnant women
  • Alcohol consumption habit (Standard Drink Unit (SDU); one SDU equals 10 grams of alcohol. Risky consumption is considered from 4 SDUs in men and 2 SDUs in women).
  • Displaced patients not assigned to the study center.
  • Patients classified as Advanced Chronic Care Model or Complex Chronic Patient.
  • Participants diagnosed with any of the following pathologies: Chronic liver diseases, including hepatic steatosis; Dementia; Active oncological diseases
  • Cognitive or affective pathology that limits the ability to collaborate with lifestyle interventions carried out at the center.
  • Patients under the care of endocrinology specialists.
  • Participation in another clinical trial involving an experimental intervention during the period of this trial.

Trial design

Primary purpose

Supportive Care

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

434 participants in 2 patient groups

FLI test implementation
Experimental group
Description:
A training session will be conducted for healthcare professionals on the risks of hepatic steatosis in patients with a body mass index (BMI) equal to or greater than 25. Additionally, professionals will be instructed in the use of the Fatty Liver Index (FLI) tool, validated for assessing the risk of steatosis. This tool will be implemented in the center's computer system, making it accessible via a link for the professionals receiving the intervention.
Treatment:
Other: FLI
control
No Intervention group
Description:
This group of healthcare professionals will continue with their usual clinical practice.

Trial contacts and locations

1

Loading...

Central trial contact

Noemí Casaponsa; M Carmen Rosas, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems